🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Amy Bregar

Massachusetts General Hospital

ORCID: 0000-0002-6593-1573

Also affiliated with Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer”.

OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.04.578

N/A

0.399DataRank · unranked

12 citations

Debra L. Richardson, Andrea R. Hagemann, Robert W. Holloway, Mark S. Reed, Melanie K Bergman +21 more

105P Immune biomarker analysis of the OVATION-2 trial, a randomized phase I/II study of IL-12 gene therapy IMNN-001 in combination with neo/adjuvant chemotherapy (NACT) in newly-diagnosed advanced epithelial ovarian cancer (EOC)

ESMO Open(2025)10.1016/j.esmoop.2025.105233

N/A

0DataRank · unranked

1 citations

Debra L. Richardson, Andrea R. Hagemann, Robert W. Holloway, Bhavana Pothuri, Jennifer Scalici +14 more

First-In-Human Trial of Encapsulated Cell-Based Protein Producers for Localized IL-2 in Patients with High-Grade Serous Ovarian Carcinoma

medRxiv(2025)10.1101/2025.11.07.25339137

N/A

0DataRank · unranked

0 citations

Samira Aghlara-Fotovat, Jake Schladenhauffen, Jonathon DeBonis, Juan Carlos Amador-Molina, Amanda Nash +24 more